Product image of Iluvien (Fluocinolone Acetonide) supplied by GNH India

Iluvien

Active Ingredient:
Fluocinolone Acetonide
Origin:
EU

Iluvien (Fluocinolone Acetonide)

Fluocinolone Acetonide, the active ingredient in Iluvien, is a corticosteroid presented as a 0.19 mg intravitreal implant for intravitreal use. It treats diabetic macular edema in adults by delivering sustained anti‑inflammatory therapy directly to the retina, reducing fluid accumulation and improving visual function.

GNH India supplies Iluvien as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, ophthalmology clinics and specialty pharmacies worldwide, ensuring consistent quality, regulatory compliance and reliable cold‑chain logistics where required, with dedicated technical support and documentation for regulatory submissions.

Manufacturer / TM Owner

Alimera Sciences Europe Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Iluvien, an ophthalmic corticosteroid, is indicated for retinal conditions characterized by vascular leakage and inflammation, specifically diabetic macular edema that persists despite prior therapy.
  • Diabetic macular edema (chronic): reduces retinal fluid accumulation, stabilizes or improves visual acuity, and provides sustained therapy for up to 36 months.
  • Diabetic macular edema (refractory to anti‑VEGF therapy): delivers continuous corticosteroid exposure, offering an alternative mechanism of action to control edema.

How It Works

  • Fluocinolone acetonide binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This action suppresses pro‑inflammatory cytokines, decreases vascular endothelial growth factor expression, and stabilizes the blood‑retinal barrier, thereby reducing ocular inflammation and vascular permeability. The sustained‑release implant maintains therapeutic intra‑vitreal concentrations for several years, ensuring continuous receptor activation and inhibition of leukocyte migration and fibroblast proliferation.

Side Effects

Fluocinolone acetonide released from the Iluvien implant may be associated with ocular adverse reactions.

Common Side Effects

  • Increased intraocular pressure (IOP)
  • Cataract formation or progression
  • Blurred or decreased vision
  • Ocular discomfort or pain
  • Floaters or visual disturbances
  • Mild anterior chamber inflammation

Serious or Rare Side Effects

  • Endophthalmitis (intraocular infection)
  • Retinal detachment or tear
  • Severe IOP elevation requiring surgical intervention
  • Persistent macular edema despite therapy
  • Implant migration or dislocation

Precautions & Warnings

When prescribing Iluvien, clinicians should consider patient‑specific risk factors and monitor ocular status regularly.

  • Monitor intraocular pressure: schedule periodic IOP measurements to detect elevation early.
  • Assess cataract development: evaluate lens status at each follow‑up visit.
  • Screen for ocular infection: avoid implantation in eyes with active infection.
  • Evaluate glaucoma history: contraindicated in uncontrolled glaucoma.
  • Pregnancy and lactation: safety unknown; use only if potential benefit justifies risk.
  • Store at ambient temperature: keep in original packaging, protect from moisture and light.

Avoid Interactions

Iluvien may interact with other ocular or systemic agents; awareness of potential additive effects is essential.

Major Interactions (Avoid)

  • Concurrent intraocular corticosteroids: additive risk of intraocular pressure rise.
  • Systemic immunosuppressants (e.g., systemic steroids, biologics): may increase infection risk.
  • CYP3A4 inhibitors (e.g., ketoconazole) in patients with systemic exposure: theoretical increase in systemic levels.

Moderate Interactions (Monitor Closely)

  • Topical non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate ocular irritation.
  • Antihypertensive eye drops (e.g., beta‑blockers): monitor IOP response.
  • Anticoagulants: consider bleeding risk during implantation procedure.

Frequently Asked Questions

Iluvien is an intravitreal implant containing fluocinolone acetonide that is prescribed to treat diabetic macular edema. It provides a sustained release of corticosteroid directly into the eye, helping to reduce retinal swelling and improve visual acuity in patients with this condition.

Fluocinolone acetonide binds to glucocorticoid receptors inside ocular cells, altering gene transcription to suppress inflammatory cytokines, lower vascular endothelial growth factor levels, and strengthen the blood‑retinal barrier. This reduces inflammation and vascular leakage that contribute to macular edema.

Iluvien is supplied as a single‑use 0.19 mg intravitreal implant. The exact dosing schedule, including the decision to implant and any re‑implantation timing, is determined by the treating ophthalmologist based on the individual patient's clinical needs.

The safety of Iluvien in pregnancy and lactation has not been established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by the prescribing physician.

To order Iluvien, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

Iluvien offers a long‑acting corticosteroid option that can last up to three years, reducing the need for frequent injections. Compared with anti‑VEGF agents, it provides an alternative mechanism by targeting inflammation. Unlike the dexamethasone implant (Ozurdex), Iluvien delivers a lower daily dose over a longer period, which may be advantageous for chronic disease control.

Iluvien should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the implant from moisture and direct light. Do not refrigerate or freeze the product, and handle it only in a controlled environment to maintain sterility before implantation.

Iluvien is implanted by a qualified ophthalmic surgeon using a sterile intravitreal injection technique. The 0.19 mg implant is placed into the vitreous cavity through the pars plana under aseptic conditions, typically in an operating‑room setting.

The most serious adverse events include significant intraocular pressure elevation that may require surgical intervention, cataract formation leading to vision loss, endophthalmitis (intraocular infection), and retinal detachment. Patients should be monitored closely for these complications throughout the treatment period.

Iluvien is contraindicated in patients with active ocular infection, uncontrolled glaucoma, known hypersensitivity to fluocinolone acetonide or any component of the implant, and in eyes that have recently undergone intraocular surgery where healing is incomplete. The prescriber must evaluate each patient’s medical history before implantation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Fluocinolone Acetonide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT